

**South Dakota Department of Social Services, Division of Medicaid Services
Pharmacy & Therapeutics (P&T) Committee Meeting Minutes**

Friday, September 7, 2018

1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD		Kelley Oehlke, PharmD	X
Dana Darger, RPh, Chair	X	Lenny Petrik, PharmD	X
James Engelbrecht, MD	X	Timothy Soundy, MD	
Deidre Van Gilder, PharmD	X	Mike Jockheck, DSS Staff	X
Mikal Holland, MD	X	Sarah Akers, DSS Staff	
Richard Holm, MD	X	Bill Snyder, DSS Staff	X
Bill Ladwig, RPh	X		

Administrative Business

The meeting was called to order by Darger at 1:03 PM. The minutes of the June meeting were presented. Ladwig made a motion to approve. Oehlke seconded the motion. Motion was approved unanimously.

New Committee Member Introduction

The committee welcomed new committee member Deidra Van Gilder, PharmD.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report for April 1, 2018 to June 30, 2018. There were a total of 1,136 PAs reviewed during this time period. There were 254 requests (22%) received via telephone and 882 requests (78%) received via fax. PA appeals information were also reviewed.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from April 1, 2018 to June 30, 2018. The top five classes were atypical antipsychotics, insulins, amphetamines, respiratory and CNS stimulants, and anticonvulsants. The top 15 therapeutic classes make up 27.64% of total claims. The committee also reviewed the top 50 drugs based on total claims cost and number of claims. The top 50 drugs by claims cost make up 11.97% of total claims. Darger noted Onfi is the 6th drug on the top 50 drug list. Darger requested in-depth utilization such as diagnosis codes, prescribers, & general member profiles (age, etc) to review at the next meeting.

Old business

Committee reviewed mometasone utilization data compared to the other nasal steroids. No changes were recommended at this time.

Committee reviewed utilization data on proton pump inhibitor packets/suspensions/ODTs. Committee requested PA form separating packets/suspensions/ODTs vs tabs/caps to review at the next meeting.

Committee reviewed the Lyrica PA fax form which included two additional diagnoses and reauthorization criteria. Ladwig motioned to approve. Oehlke seconded the motion. Motion was approved unanimously.

Committee reviewed the PCSK9 PA fax form which included a criteria change and reauthorization criteria. Ladwig motioned to approve. Holm seconded the motion. Motion was approved unanimously.

Committee reviewed new PA criteria for Aimovig. Engelbrecht motioned to approve PA as presented and review utilization at the next meeting. Ladwig seconded the motion. Motion was approved unanimously.

New business

Committee discussed the advantages and disadvantages of a preferred drug list (PDL). Committee requested more information.

The next meeting is scheduled for December 7, 2018. Tentative meeting date for March 2019 date is March 8, 2019. Ladwig made a motion to adjourn. Holm seconded the motion. The meeting adjourned at 2:30 PM.